Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive

Metabolism: Clinical and Experimental

Volumn 45, Issue 2, 1996, Pages 190-195

  Maggard, Melinda A ^b   Catlin, Elizabeth A ^b   Hudson, Peter L ^b   Donahoe, Patricia K ^b   MacLaughlin, David T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MUELLERIAN INHIBITING FACTOR; PHOSPHATASE; VANADIC ACID;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

EID: 0029986145     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90052-9     Document Type: Article

References (36)

1. Blanchard MG, Josso N: Source of anti-Mullerian hormone synthesized by the fetal testis: Mullerian inhibiting activity of fetal bovine Sertoli cells in tissue culture. Pediatr Res 8:968-971, 1974
2. Budzik GP, Powell SM, Kamagata S, et al: Mullerian inhibiting substance fractionation by dye affinity chromatography. Cell 34:307-314, 1983
3. Donahoe PK, Ito Y, Price JM, et al: Mullerian inhibiting substance activity in bovine fetal, newborn and prepubertal testes. Biol Reprod 16:238-243, 1977
4. Vigier B, Picard JY, Tran D, et al: Production of anti-Mullerian hormone: Another homology between Sertoli and granulosa cells. Endocrinology 114:1315-1320, 1984
5. Takahashi M, Hayashi M, Manganaro TF, et al: The ontogeny of Mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle. Biol Reprod 35:447-453, 1986
6. Kim JH, Seibel MM, MacLaughlin DT, et al: The inhibitory effects of Mullerian inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J Clin Endocrinol Metab 7:911-917, 1992
7. Takahashi M, Koide SS, Donahoe P: Mullerian inhibiting substance as oocyte meiosis inhibitor. Mol Cell Endocrinol 47:225-234, 1986
8. Ueno S, Manganaro TF, Donahoe PK: Human recombinant Mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology 123:1652-1659, 1988
9. Donahoe PK, Swann DA, Hayashi A, et al: Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science 205:913-915, 1979
10. Fuller AR Jr, Krane BA, Budzik GP, et al: Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol 22:135-148, 1985
11. Chin T, Parry RL, Donahoe PK: Human Mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res 51:2101-2106, 1991
12. Parry RL, Chin T, Epstein J, et al: Recombinant human Mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Res 52:1182-1186, 1992
13. Boveri JF, Parry RL, Ruffin WK, et al: Transfection of the Mullerian inhibiting substance gene inhibits local and metastatic tumor growth. Int J Oncol 2:135-143, 1993
14. Hudson P, Dougas I, Donahoe PK, et al: An immunoassay to detect human Mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 70:16-22, 1990
15. Budzik GP, Powell SM, Kamagata S, et al: A possible purification of Mullerian inhibiting substance and a model for its mechanism of action, in Lash JW, Saxen J (eds): Developmental Mechanisms: Normal and Abnormal. New York, NY, Liss, 1985, pp 207-223
16. Coughlin JP, Donahoe PK, Budzik GP, et al: Mullerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase. Mol Cell Endocrinol 49:75-86, 1987
17. MacLaughlin DT, Hudson PL, Graciano AL, et al: Mullerian duct regression and antiproliferative bioactivities of Mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology 131:291-296, 1992
18. Kurian MS, Sainz de la Cuesta R, Waneck GL, et al: Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo. Clin Cancer Res 1:343-349, 1995
19. Cate RL, Donahoe PK, MacLaughlin DT: Mullerian inhibiting substance, in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology, vol 95. New York, NY, Springer-Verlag, 1990, pp 179-210
20. Catlin EA, Uitvlugt ND, Donahoe PK, et al: Mullerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes. Metabolism 40:1178-1184, 1991
21. Cigarroa FG, Coughlin JP, Donahoe PK, et al: Recombinant human Mullerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase. Growth Factors 1:179-191, 1989
22. Ragin RC, Donahoe PK, Kenneally MK, et al: Human Mullerian inhibiting substance: Enhanced purification imparts biochemical stability and restores antiproliferative effects. Prot Purif Expr 3:236-245, 1992
23. Catlin EA, Ezzell RM, Donahoe PK, et al: Identification of a receptor for human Mullerian inhibiting substance. Endocrinology 133:3007-3013, 1993
24. Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye affinity. Anal Biochem 72:248-254, 1976
25. Takai A, Bialojan C, Troschka M, et al: Smooth muscle myosin phosphatase inhibition and force enhancement by black sponge toxin. FEBS Lett 217:81-84, 1987
26. 2+-dependent, sulfhydryl-sensitive proteolytic system in A431 cells. J Biol Chem 257:9845-9848, 1982
27. Auberger P, Falquerho L, Contreres JO, et al: Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 57:631-640, 1989
28. Wilson CA, di Clemente N, Ehrenfels C, et al: Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-β superfamily. Mol Endocrinol 7:247-257, 1993
29. Klagsbrun M, Baird A: A dual receptor system is required for basic fibroblast growth factor activity. Cell 67:229-231, 1991
30. Kawamoto T, Mendelsohn J, Le A, et al: Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem 259:7761-7766, 1984
31. Goldkorn T, Mendelsohn J: Transforming growth factor beta modulates phosphorylation of the epidermal growth factor receptor and proliferation of A431 cells. Cell Growth Differ 3:101-109, 1992
32. He WW, Gustafson ML, Hirobe S, et al: The developmental expression of four novel serine/threonine kinase receptors homologous to the activin/TGF-β II receptor family. Dev Dynam 196:133-142, 1993
33. Baarends WM, van Helmond MJL, Post M, et al: A novel member of the serine/threonine kinase receptor family is expressed in the gonads and in the mesenchymal cells adjacent to the Mullerian duct. Development 120:189-197, 1994
34. Wang T, Donahoe PK, Zervos AJ: Specific interaction of type I TGF-B family with the immunophilin FKBP-12. Science 265:674-676, 1994
35. Hutson JM, Fallat ME, Kamagata S, et al: Phosphorylation events during Mullerian duct regression. Science 223:586-589, 1984
36. Gruppuso PA, Mikumo R, Brautigan DL, et al: Growth arrest induced by transforming growth factor B1 is accompanied by protein phosphatase activity in human keratinocytes. J Biol Chem 266:3444-3448, 1991